Lower-extremity dynamometry as a novel outcome measure in a double-blind, placebo-controlled, feasibility trial of intravenous immunoglobulin (IVIG) for HIV associated myelopathy

Jessica Robinson-Papp, Mary Catherine George, Alexandra Nmashie, Donald Weisz, David M. Simpson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: Open-label data suggest that intravenous immunoglobulin (IVIG) might improve lower extremity strength in human immunodeficiency virus (HIV)-associated myelopathy (HIVM), a rare but debilitating neurologic complication of HIV. We sought to determine the feasibility of testing the efficacy of IVIG for HIVM more rigorously. Design: We conducted a randomized, double-blind, placebo-controlled feasibility trial of IVIG for HIVM, using dynamometry as an outcome measure (Clinical Trial No. NCT01561755). Setting: The study took place in an academic medical center in New York, New York Participants: Only 12 participants were enrolled in four years; critical impediments to the study were the rarity of patients with new HIVM diagnoses and prior exposure to IVIG in patients with an established diagnosis. Measurements: Dynamometry of hip flexion, knee flexion, and ankle dorsiflexion were measured; the HIV Dementia Motor Score (HDMS); and the two-minute timed walk test were utilized. Results: Recruitment was the major feasibility issue. Dynamometry was generally well-tolerated, had good test-retest reliability (r=0.71–0.86, p<0.02 for all muscle groups), and good inter-item reliability as judged by the correlations between the muscle groups (r=0.76-0.81, p=0.001–0.005). Dynamometry was valid and clinically meaningful based on its correlations with the HDMS and the two-minute timed walk test. Conclusion: We conclude that an adequately powered clinical trial of IVIG for HIVM would likely require a prolonged recruitment period and multiple participating sites. Lower limb dynamometry is a useful outcome measure for HIVM, which might also be useful in other HIV-related gait disorders.

Original languageEnglish
Pages (from-to)28-32
Number of pages5
JournalInnovations in Clinical Neuroscience
Volume15
Issue number1-2
StatePublished - 1 Jan 2018

Keywords

  • Dynamometry
  • Human immunodeficiency virus (HIV)
  • Intravenous immunoglobulin (IVIG)
  • Myelopathy

Fingerprint

Dive into the research topics of 'Lower-extremity dynamometry as a novel outcome measure in a double-blind, placebo-controlled, feasibility trial of intravenous immunoglobulin (IVIG) for HIV associated myelopathy'. Together they form a unique fingerprint.

Cite this